Certain Noteholders of Monitronics International, Inc.

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
48
Certain Noteholders of Monitronics International, Inc. Release Information About Transaction Discussions

NEW YORK, Aug. 20, 2018 (GLOBE NEWSWIRE) -- Stroock & Stroock & Lavan LLP on behalf of the holders (the “Disclosing Noteholders”) of over 65% in principal amount of the 9.125% Senior Notes due 2020 (the “Senior Notes”) issued by Monitronics International, Inc. (the “Company”) are publicly disclosing information to supplement the disclosure made by the Company and its parent entity, Ascent Capital Group, Inc. (“Ascent”), in their respective Form 8-K Reports issued on August 17, 2018 (collectively, the “8-K”).  The Disclosing Noteholders are members of an ad hoc group of holders of Senior Notes that is being advised by Stroock & Stroock & Lavan LLP and Houlihan Lokey, Inc.

As stated in the 8-K, the Company proposed to the Disclosing Noteholders an exchange of the Senior Notes into new unsecured notes of the Company along with a tender offer for Senior Notes by Ascent using up to $100 million of Ascent’s cash (as described more fully below) and the Disclosing Noteholders proposed to the Company an exchange of the Senior Notes into new second lien secured notes of the Company along with a repayment of the Company’s term loan of $100 million. The proposal by the Disclosing Noteholders provided that the second lien note exchange would be the preferred alternative and that the Disclosing Noteholders would support an unsecured note exchange only if the second lien note exchange proved unsuccessful.  The Company and the Disclosing Noteholders and their respective advisors engaged in negotiations over these proposals between August 2, 2018 and August 17, 2018.  To the knowledge of the Disclosing Noteholders, the Company did not present any of the proposals that were discussed to the holders of the Company’s term loans or revolving loans.

The last proposal made by the Company to the Disclosing Noteholders for both the second lien note exchange and the unsecured note exchange included the following elements:

A.  Second Lien Note Exchange

  1. The Company would seek an amendment to its Credit Agreement dated as of March 23, 2012, with Bank of America, N.A., and certain other lenders (the “Credit Agreement”) to allow the Senior Notes to be exchanged into new second lien secured notes (the “Second Lien Notes”).  In addition, Ascent would use $100 million in cash to pay down the term loans under the Credit Agreement.
     
  2. The Company would offer to exchange any or all of the Senior Notes for Second Lien Notes on a par for par basis (if tendered by a specified date) or at a rate of $950 for every $1,000 tendered (if tendered after the specified date). 
     
  3. The Second Lien Notes would mature on April 30, 2023 and accrue cash interest at a rate of 6.50% and pay-in-kind interest at a rate of 3.50%.
     
  4. The exchange for Second Lien Notes would only become effective upon the participation of holders of 85% in principal amount of the Senior Notes and the receipt of consents to the related Credit Agreement amendment from the requisite lenders under the Credit Agreement.

B.  Tender Offer and Unsecured Note Exchange

  1. Ascent would use $100 million in cash (the “Tender Amount”) to tender for Senior Notes in a modified Dutch Auction process at 75.0 - 87.5% of par value.  Certain noteholders would backstop the tender offer at a price of 87.5% of par value. 
     
  2. The Senior Notes acquired by Ascent in the tender offer would remain outstanding and accrue cash interest at a rate of 7.50% and be guaranteed by the Company’s subsidiaries on a basis subordinated to the New Senior Notes (as defined below).
     
  3. The Company would offer to exchange any or all of the Senior Notes not acquired by Ascent in the tender offer for new senior notes (the “New Senior Notes”) on a par for par basis (if tendered into the exchange by a specified date) or at a rate of $950 for every $1,000 tendered (if tendered into the exchange after the specified date). 
     
  4. Exchanging noteholders would also receive penny warrants to purchase 10% of Ascent’s common stock, with a strike price equal to the greater of (i) 150% of the pre-launch trading price, or (ii) $5.00 per share. 
     
  5. The New Senior Notes would mature on April 30, 2023 and accrue cash interest at a rate of 7.50% and pay-in-kind interest at a rate of 4.00% and be guaranteed by all restricted subsidiaries guaranteeing the revolving and term loan facilities.   
     
  6. The tender offer and exchange would only become effective upon participation by Noteholders holding no less than 65% in principal amount of the Senior Notes. 

While the Disclosing Noteholders engaged in good faith negotiations with the Company to reach agreement on the terms of the proposed exchange offers, they rejected the Company’s last proposal. The Company and the Disclosing Noteholders subsequently were unable to reach an agreement and, as disclosed in the 8-K, have ceased discussions.

Prior to the discussions with the Company, certain holders of the Senior Notes that collectively hold more than 65% in principal amount of the Senior Notes, including certain of the Disclosing Noteholders, entered into a cooperation agreement, dated July 31, 2018 (the “Cooperation Agreement”), which, among other things, requires the consent of each such noteholder for any such noteholder to agree to the terms of a transaction with the Company relating to a restructuring of the Company’s indebtedness. The Cooperation Agreement currently expires on September 29, 2018.

No assurances can be made that (a) any transaction described herein or other transaction involving the Senior Notes will be implemented or (b) any definitive agreements will be reached between the Company and the Disclosing Noteholders with respect to the Senior Notes.

Contact Person: 
Kristopher M. Hansen
STROOCK
180 Maiden Lane, New York, NY 10038
D: 212.806.6056

 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Stavian Group Eyes AI-Driven Southeast Asia Growth

Updated Category News Views 62

AI and Infrastructure: A New Chapter for Southeast Asia What does Southeast Asia's future look like with AI steering the ship? Well, there's a fresh breeze of change blowing, and right at the heart of it stands Stavian Group. At the recently held inaugural Fortune SEA500 Summit in Ho Chi Minh City, this conglomerate threw its hat into the ring, painting a vision of growth...

Continue Reading
ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 299

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 351

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 343

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Cultural Tech Fusion: The Asia-Pacific Way Forward

Updated Category News Views 29

A High-Tech Twist on Traditional Culture You ever walk into a room and see a robot perform kung fu? I'll admit, it caught me off guard at first. But that's exactly what happened at the "Enduring Heritage, Harmonious Asia-Pacific" special exhibition in Shenzhen. With all the usual high-ranking execs and cultural bigwigs there, nobody expected a showcase where Wing Chun...

Continue Reading
FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

Updated Category News Views 123

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

Continue Reading
CureGene's Evategrel Aims for Breakthrough in Stroke Care

Updated Category News Views 69

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 250

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 119

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 456

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading

Top 5 Most Recently Viewed Articles

Brazil Potash Secures $75 Million Equity Line for Growth

Updated Category News Views 167

Brazil Potash Secures Key Funding for Autazes Project Brazil Potash Corp. (“Brazil Potash” or the “Company”) (NYSE American: GRO), a prominent player in mineral development focused on potash mining, has recently finalized a significant agreement establishing an equity line of credit (ELOC) with Alumni Capital LP. This collaboration signals a crucial step in...

Continue Reading
AGCO Completes Major Strategic Shift Transforming Business Focus

Updated Category News Views 101

AGCO Completes Divestiture of Grain & Protein Business AGCO Corporation (NYSE: AGCO), a leading firm in agricultural machinery and precision ag technology, has finalized the sale of the majority of its Grain & Protein business to American Industrial Partners (AIP) in an all-cash deal valued at around $700 million. This significant transition emphasizes AGCO's focus on...

Continue Reading
Vincent Bouatou Takes the Helm as CTO at IDEMIA Public Security

Updated Category News Views 64

Vincent Bouatou Appointed as Chief Technology Officer With a wealth of experience in the technology sector, Vincent Bouatou has been officially announced as the Chief Technology Officer (CTO) of IDEMIA Public Security. His extensive background in driving technological innovations positions him to make significant strides in the biometric technology industry. Driving...

Continue Reading
MedX Holdings, Inc. Reaches New Heights in Q1 Revenue Growth

Updated Category News Views 171

MedX Holdings, Inc. Reports Extraordinary Q1 Revenue Gains MedX Holdings, Inc. (OTC: MEDH) is delighted to share its impressive financial results for the first quarter of 2025. With record revenue levels and strategic advancements, this milestone reflects the company's commitment to becoming a prominent player in cannabis retail, technology, and franchise development....

Continue Reading
Erste Group Upgrades WW Grainger Stock Amid Positive Outlook

Updated Category News Views 74

Erste Group upgraded WW Grainger (NYSE: GWW) from Hold to Buy back in mid-2024, showing that the desks had a new favorite. With a return on equity at a whopping 59%, Grainger's performance left many competitors in the dust, making it a must-watch stock for anyone looking to get into industrial supply chains. What's Driving the Upgrade? The reasons behind this rating shift...

Continue Reading